Does Charles River Laboratories International Deserve a Place in Your Portfolio?

NYSE: CRL | Charles River Laboratories International Inc. News, Ratings, and Charts

CRL – The shares of Charles River Laboratories (CRL) have plunged in price despite the company’s solid results. So, can they rebound by the company leveraging its broad portfolio of products and services? Read on. Let’s find out.

Charles River Laboratories International, Inc. (CRL) in Wilmington, Mass., is a non-clinical contract research organization that provides international drug discovery, non-clinical development, and safety testing services. The company and Valo Health, Inc. recently launched LogicaTM to provide their clients with highly advanceable leads and candidates. 

However, CRL is expected to be impacted by unfavorable movements in foreign currency exchange rates in the current year.

CRL’s 37.64% trailing-12-month gross profit margin is 32.2% lower than the 55.47% industry average. The stock has declined 11.8% over the past month and 48.4% over the past nine months to close yesterday’s trading session at $223.48. In addition, it is currently trading 51.4% below its 52-week high of $460.21, which it hit on Sept. 24, 2021. So, CRL’s near-term prospects look uncertain.

Here is what could influence CRL’s performance in the upcoming months:

Robust Financials

CRL’s total sales increased 10.8% year-over-year to $913.93 billion in the first quarter, which ended March 26, 2022. Its operating income grew 20.2% year-over-year to $148.78 million, while its net income came in at $95.23 million, representing a 48.9% year-over-year increase. Also, its EPS came in at $1.81, up 50.8% year-over-year.

Favorable Analyst Estimates

For its fiscal year 2022, analysts expect CRL’s EPS and revenue to grow 12.6% and 14.2% year-over-year to $11.62 and $4.04 billion, respectively. In addition, its EPS is expected to grow at 14.7% per annum over the next five years. Furthermore, Wall Street analysts expect the stock to hit $337.09 in the near term, indicating a potential 50.8% upside.

Stretched Valuation

In terms of forward P/B, CRL’s 3.70x is 37.3% higher than the 2.70x industry average. Likewise, its 13.70x forward EV/EBITDA is higher than the 12.93x industry average.

POWR Ratings Don’t Indicate Enough Upside

CRL has an overall C rating, which equates to a Neutral in our POWR Ratings system. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.

Our proprietary rating system also evaluates each stock based on eight distinct categories. CRL has a C grade for Value, which is in sync with its higher-than-industry valuation ratios.

The stock has a C grade for Stability, which is consistent with its beta of 1.27.

CRL is ranked #19 out of 50 stocks in the D-rated Medical – Diagnostics/Research industry. Click here to access CRL’s ratings for Quality, Growth, Momentum, and Sentiment.

Click here to checkout our Healthcare Sector Report for 2022

Bottom Line

CRL is currently trading below its 50-day and 200-day moving averages of $263.44 and $346.67, respectively, indicating a downtrend. Furthermore, it could keep retreating due to concerns over currency headwinds in the near term. So, the stock looks overvalued at the current price level, and we think it could be wise to wait for a better entry point in the stock.

How Does Charles River Laboratories (CRL) Stack Up Against its Peers?

While CRL has an overall POWR Rating of C, one might want to consider investing in the following Medical – Diagnostics/Research stocks with an A (Strong Buy) rating: Global Cord Blood Corporation (CO), Qiagen N.V. (QGEN), and Agilent Technologies Inc. (A).

Want More Great Investing Ideas?

3 Stocks to DOUBLE This Year


CRL shares were trading at $225.32 per share on Thursday afternoon, up $1.84 (+0.82%). Year-to-date, CRL has declined -40.20%, versus a -14.36% rise in the benchmark S&P 500 index during the same period.


About the Author: Nimesh Jaiswal


Nimesh Jaiswal's fervent interest in analyzing and interpreting financial data led him to a career as a financial analyst and journalist. The importance of financial statements in driving a stock’s price is the key approach that he follows while advising investors in his articles. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
CRLGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Investors: Are You Ready for November?

The S&P 500 (SPY) tumbled to end October. Is that a harbinger of more downside to come? Or will the bull market return with gusto? Investment pro Steve Reitmeister shares his time market views including a preview of his favorite stocks. Get the full story below...

3 Cybersecurity Stocks Defending Against Digital Threats

The demand for cybersecurity solutions is rising as digital threats and sophisticated cyberattacks continue to escalate. Therefore, it might be wise to keep track of cybersecurity stocks, CrowdStrike (CRWD), Palo Alto Networks (PANW), and Fortinet (FTNT), as they offer innovative solutions presenting further growth opportunities. Continue reading...

3 Oil Stocks With High Upside as Global Demand Rebounds

The outlook for oil demand growth appears promising despite economic uncertainties and worldwide supply deficit. Amid this, investing in quality oil stocks Enterprise Products Partners (EPD), Marathon Oil (MRO), and Plains All American Pipeline (PAA) could be ideal as global demand rebounds. Read more...

3 Tech Stocks Under $10 That Could Deliver Big Gains

The technology industry is booming, driven by breakthroughs and significant government investments. Thus, incorporating affordable tech stocks, Sprinklr (CXM), Sabre Corporation (SABR), and Cricut (CRCT) into your portfolio provides an accessible entry point to capitalize on the industry’s growth. Read more…

2 Concerns for Investors in October

The S&P 500 (SPY) may be touching all time highs...but recent action points to concerns on 2 fronts: inflation and earnings. Investment veteran Steve Reitmeister shares his views on these 2 timely topics along with a preview of his top stocks to buy now.

Read More Stories

More Charles River Laboratories International Inc. (CRL) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CRL News